Eisai Announce Establishment of New Pharmaceutical Marketing Subsidiary in Belgium

LONDON, September 28 /PRNewswire/ --

- For the Attention of Business and Healthcare Editors

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito)
announced today that the Company established its pharmaceutical marketing
subsidiary, Eisai SA/NV in Belgium. Eisai SA/NV is owned by Eisai Europe
Limited (Headquarters: London, President: Yutaka Tsuchiya).

Serving as the regional sales hub for Benelux (Belgium, Netherlands and
Luxembourg), which is the sixth largest market in the EU, Eisai SA/NV will
start marketing activities in all three Benelux countries in due course with
the focus on the anti-epileptic drugs Zonegran(R) and Inovelon(R), as well as
the non-opioid severe chronic pain agent Prialt(R). In addition, Eisai SA/NV
plans to start promotion of its Alzheimer's disease treatment Aricept(R) in
Belgium and Luxembourg with its co-promotion partner.

Eisai plans further expansion of its business operations across Europe
and will undertake "Independent Marketing" activities by using their own
sales and marketing personnel, tailored for each county. Eisai SA/NV is the
Company's ninth marketing subsidiary in Europe, and brings the total number
of countries where Eisai undertake sales and marketing operations through its
own distribution channels to 17, including; the United Kingdom, France,
Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark,
Finland, Norway, Portugal, Iceland, Belgium, Netherlands, and Luxembourg.

Through stable provision of Eisai's products, further enabled by the
establishment of new subsidiaries and branches, Eisai is committed to
increasing patient value and fulfilling the diverse needs of patients and
their families throughout Europe.

----------------------------------------------------------
    Company Outline

    Company Name: Eisai SA/NV

    Establishment Date: September 10, 2007 (Local Time)

    Capital: EUR7 million (approx. 1,100 million yen)

    Location: Brussels, Belgium

    Operations: Promoting the sale of pharmaceutical products
    ----------------------------------------------------------